Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 50

Sort by

Sort Order Select

Journal Articles

Molecular Expression Differences in Blood Mononuclear Cells in Patients with AL Amyloidosis

David Kaplan, Eric Christian, Jason Valent, Faiz Anwer, Shahzad Raza, Sandra Mazzoni, Christy J. Samaras, Louis S. Williams, Danai Dima, Kelly Shepherd, Jared Fennema, Sherry Fada, Megan Nakashima, Mazen Hanna, Hillard M. Lazarus, Jack Khouri

Blood (2023) 142 (Supplement 1): 5031.

https://doi.org/10.1182/blood-2023-180735

Published: 2023

Journal Articles

Outcomes of Venetoclax-Based Therapy in Patients with Daratumumab-Refractory t(11;14) Positive Light Chain Amyloidosis

Mark Orland, Danai Dima, Fauzia Ullah, Hussein Awada, Diana Basali, Beth M. Faiman, Cynthia Scott, Sandra Mazzoni, Louis S. Williams, Christy J. Samaras, Jason Valent, Faiz Anwer, Shahzad Raza, Jack Khouri

Blood (2023) 142 (Supplement 1): 2031.

https://doi.org/10.1182/blood-2023-183030

Published: 2023

Journal Articles

Outcomes of Lymphoma and Multiple Myeloma Patients Following Inpatient Antineoplastic Treatment

Blood (2023) 142 (Supplement 1): 7245.

https://doi.org/10.1182/blood-2023-190304

Published: 2023

Journal Articles

Insights into Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: A 12-Year Experience of a Large Academic Center

Danai Dima, Fauzia Ullah, Serhan Unlu, Diana Basali, Mahir Khan, Abdullah Saeed Khan, Xuefei Jia, Majid Jaberi-Douraki, Beth M. Faiman, Sandra Mazzoni, Louis S. Williams, Christy J. Samaras, Jason Valent, Faiz Anwer, Jack Khouri, Shahzad Raza

Blood (2023) 142 (Supplement 1): 3407.

https://doi.org/10.1182/blood-2023-181365

Published: 2023

Journal Articles

Outcomes of Salvage VDT-PACE-like Regimens in Relapsed-Refractory Multiple Myeloma: 10-Year Experience of a Large Academic Institution

Arooj Ahmed, Danai Dima, Kerri Row, Fauzia Ullah, Hussein Awada, Diana Basali, Heena Kurish, Mikhaila Rice, Joslyn Rudoni, Marissa Duco, Beth M. Faiman, Jack Khouri, Sandra Mazzoni, Louis S. Williams, Shahzad Raza, Christy J. Samaras, Jason Valent, Faiz Anwer

Blood (2023) 142 (Supplement 1): 4724.

https://doi.org/10.1182/blood-2023-182972

Published: 2023

Journal Articles

An Ensemble Machine Learning Model Using Gradient Boosting Identifies Patients with Disease Progression in Newly Diagnosed Multiple Myeloma

Louis S. Williams, Bardia Khosravi, Marko Velimirovic, Jack Khouri, Shahzad Raza, Sandra Mazzoni, Christy J. Samaras, Hussein Awada, Danai Dima, Jason Valent, Faiz Anwer

Blood (2023) 142 (Supplement 1): 1990.

https://doi.org/10.1182/blood-2023-188762

Published: 2023

Journal Articles

Neighborhood Socioeconomic Disadvantage and Distance from Treatment Center Do Not Impact Survival Outcomes of Patients with Non-Hodgkin Lymphoma and Multiple Myeloma Treated with CAR T-Cell Therapies

Agrima Mian, Danai Dima, Betty K. Hamilton, Allison Winter, Jack Khouri, Louis S. Williams, Shahzad Raza, Deepa Jagadeesh, Aaron T. Gerds, Robert M. Dean, Matt Kalaycio, Claudio Brunstein, Craig S Sauter, Faiz Anwer, Brian T. Hill, Paolo Caimi

Blood (2023) 142 (Supplement 1): 7399.

https://doi.org/10.1182/blood-2023-188712

Published: 2023

Journal Articles

The Significance of a “MGUS” Tumor Board

Sandra Mazzoni, Jack Khouri, Louis S. Williams, Beth M. Faiman, Saveta Mathur, Cynthia Scott

Blood (2023) 142 (Supplement 1): 3719.

https://doi.org/10.1182/blood-2023-185050

Published: 2023

Journal Articles

Intravenous Immunoglobulin Prophylaxis Is Associated with Decreased Rate of Infection-Related Hospitalizations in Multiple Myeloma Patients

Michael Sheu, Sofia Molina Garcia, Meera Patel, Lauren M Granat, Puneet Dhillon, Hussein Awada, Faiz Anwer, Jack Khouri, Louis S. Williams, Joslyn Rudoni, Aneela Majeed

Blood (2022) 140 (Supplement 1): 7251–7252.

https://doi.org/10.1182/blood-2022-158472

Published: 2022

Journal Articles

Hypercalcemia: A Risk Factor for Early Disease Progression and Poor Survival in Cytogenetically Standard-Risk Multiple Myeloma

Lauren M Granat, Hong Li, Faiz Anwer, Michael Sheu, Beth M. Faiman, Jack Khouri, Sandra Mazzoni, Jason Valent, Christy J. Samaras, Rajshekar Chakraborty, Chakra P Chaulagain, Willem J. van Heeckeren, Louis S. Williams

Blood (2022) 140 (Supplement 1): 4290–4291.

https://doi.org/10.1182/blood-2022-168040

Published: 2022

Journal Articles

Contemporary Use of VTD-PACE As Bridge Therapy in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma

Heena P Kurish, Kerri Row, Austin Kurkowski, Mikhaila Rice, Joslyn Rudoni, Jack Khouri, Sandra Mazzoni, Christy J. Samaras, Louis S. Williams, Willem van Heeckeren, Jason Valent, Faiz Anwer

Blood (2022) 140 (Supplement 1): 12496–12497.

https://doi.org/10.1182/blood-2022-162821

Published: 2022

Journal Articles

Improved Survival Outcomes for Intensive Versus Standard Chemoimmunotherapy in Primary Mediastinal B-Cell Lymphoma: A Meta-Analysis of 4068 Patients

Michael Roderick Cook, Lacey S. Williams, Scott C Dorris, Paul Kolm, Kieron Dunleavy

Blood (2022) 140 (Supplement 1): 9567–9568.

https://doi.org/10.1182/blood-2022-162852

Published: 2022

Journal Articles

Variability in Pattern of Mutational Signatures in Multiple Myeloma As a Function of Racial Origin

Blood (2022) 140 (Supplement 1): 430–432.

https://doi.org/10.1182/blood-2022-167390

Published: 2022

Journal Articles

Assessment of Major Adverse Cardiac Events (MACE) and Arrhythmias in Patients with Large B-Cell Lymphoma Undergoing Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Impact of Baseline Cardiac Biomarkers

Haikoo Shah, Danielle O'Conke, Ran Zhao, Akansha Jalota, Manishkumar S. Patel, Allison Winter, Louis S. Williams, Jack Khouri, Deepa Jagadeesh, Faiz Anwer, Robert M. Dean, Betty K. Hamilton, Ronald M. Sobecks, Brad Pohlman, Paolo F. Caimi, Craig S. Sauter, Neetu Gupta, Brian T. Hill

Blood (2022) 140 (Supplement 1): 4673–4675.

https://doi.org/10.1182/blood-2022-169412

Published: 2022

Journal Articles

Validation of the CIBMTR Scoring System in Predicting Early Relapse of Multiple Myeloma Post Autologous Hematopoietic Cell Transplant

Hussein Awada, Adel Hajj Ali, Danai Dima, Lauren M. Granat, Michael Sheu, Puneet Dhillon, Mikhaila Rice, Heena P Kurish, Louis S. Williams, Faiz Anwer, Jack Khouri

Blood (2022) 140 (Supplement 1): 7217–7218.

https://doi.org/10.1182/blood-2022-165777

Published: 2022

Journal Articles

Long-Term Outcomes of Delayed Neutrophil Engraftment Following Autologous Hematopoietic Cell Transplant in Multiple Myeloma

Hussein Awada, Adel Hajj Ali, Beth M. Faiman, Allison Winter, Sandra Mazzoni, Christy J. Samaras, Craig S. Sauter, Willem J. van Heeckeren, Robert M. Dean, Brad Pohlman, Brian T. Hill, Jason Valent, Ronald M. Sobecks, Louis S. Williams, Deepa Jagadeesh, Betty K. Hamilton, Matt Kalaycio, Jack Khouri, Faiz Anwer

Blood (2022) 140 (Supplement 1): 12924–12925.

https://doi.org/10.1182/blood-2022-170385

Published: 2022

Journal Articles

Long-Term Outcomes of Autologous Hematopoietic Cell Transplant of Multiple Myeloma: A 10 Year Follow up Study

Blood (2022) 140 (Supplement 1): 12920–12921.

https://doi.org/10.1182/blood-2022-168262

Published: 2022

Journal Articles

Risk of Venous Thromboembolism in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplant

Blood (2022) 140 (Supplement 1): 10596–10597.

https://doi.org/10.1182/blood-2022-168810

Published: 2022

Journal Articles

External Validation of the Saved Score for Venous Thromboembolism Risk Stratification in Patients with Multiple Myeloma Receiving Immunomodulatory Drugs

Danai Dima, Ang Li, Lauren M. Granat, Puneet Dhillon, Carmelo Gurnari, Anirudh Yalamanchali, Saeid Mirzai, Wei Wei, Beth M. Faiman, Louis S. Williams, Sandra Mazzoni, Christy J. Samaras, Faiz Anwer, Jason Valent, Jack Khouri

Blood (2022) 140 (Supplement 1): 11299–11300.

https://doi.org/10.1182/blood-2022-165722

Published: 2022

Journal Articles

The Role of Corrected Dlco in Predicting Relapse and Mortality Post Autologous Hematopoietic Cell Transplantation in Multiple Myeloma

Blood (2022) 140 (Supplement 1): 10592–10593.

https://doi.org/10.1182/blood-2022-168433

Published: 2022

NARROW

Molecular Expression Differences in Blood Mononuclear Cells in Patients with AL Amyloidosis

Outcomes of Venetoclax-Based Therapy in Patients with Daratumumab-Refractory t(11;14) Positive Light Chain Amyloidosis

Outcomes of Lymphoma and Multiple Myeloma Patients Following Inpatient Antineoplastic Treatment

Insights into Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: A 12-Year Experience of a Large Academic Center

Outcomes of Salvage VDT-PACE-like Regimens in Relapsed-Refractory Multiple Myeloma: 10-Year Experience of a Large Academic Institution

An Ensemble Machine Learning Model Using Gradient Boosting Identifies Patients with Disease Progression in Newly Diagnosed Multiple Myeloma

Neighborhood Socioeconomic Disadvantage and Distance from Treatment Center Do Not Impact Survival Outcomes of Patients with Non-Hodgkin Lymphoma and Multiple Myeloma Treated with CAR T-Cell Therapies

The Significance of a “MGUS” Tumor Board

Intravenous Immunoglobulin Prophylaxis Is Associated with Decreased Rate of Infection-Related Hospitalizations in Multiple Myeloma Patients

Hypercalcemia: A Risk Factor for Early Disease Progression and Poor Survival in Cytogenetically Standard-Risk Multiple Myeloma

Contemporary Use of VTD-PACE As Bridge Therapy in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma

Improved Survival Outcomes for Intensive Versus Standard Chemoimmunotherapy in Primary Mediastinal B-Cell Lymphoma: A Meta-Analysis of 4068 Patients

Variability in Pattern of Mutational Signatures in Multiple Myeloma As a Function of Racial Origin

Assessment of Major Adverse Cardiac Events (MACE) and Arrhythmias in Patients with Large B-Cell Lymphoma Undergoing Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Impact of Baseline Cardiac Biomarkers

Validation of the CIBMTR Scoring System in Predicting Early Relapse of Multiple Myeloma Post Autologous Hematopoietic Cell Transplant

Long-Term Outcomes of Delayed Neutrophil Engraftment Following Autologous Hematopoietic Cell Transplant in Multiple Myeloma

Long-Term Outcomes of Autologous Hematopoietic Cell Transplant of Multiple Myeloma: A 10 Year Follow up Study

Risk of Venous Thromboembolism in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplant

External Validation of the Saved Score for Venous Thromboembolism Risk Stratification in Patients with Multiple Myeloma Receiving Immunomodulatory Drugs

The Role of Corrected Dlco in Predicting Relapse and Mortality Post Autologous Hematopoietic Cell Transplantation in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only